ZEVRA THERAPEUTICS, INC. (ZVRA)
↓ Download CSV- Sector Manufacturing
- Incorporated DE
- Fiscal year ends Dec 31
In fiscal 2025, ZEVRA THERAPEUTICS, INC. reported revenue of $106.47M, up 350.9% from the prior year. The company was profitable, with a net margin of 78.2%. It held $284.73M in total assets against $130.07M in total liabilities.
Key ratios (FY2025)
-59.1%
Operating margin
78.2%
Net margin
53.8%
Return on equity
+350.9%
Revenue growth (YoY)
| Metric (FY) | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $106.47M | $23.61M | $27.46M | $10.16M | $28.65M | $13.29M | $12.84M | $0 | — | — |
| Cost of Revenue | — | — | $2.94M | $222.0K | $2.06M | — | — | — | — | — |
| Operating Income | -$62.94M | -$87.00M | -$49.60M | -$42.56M | $7.73M | -$5.61M | -$20.34M | -$55.90M | -$33.37M | -$37.48M |
| Net Income | $83.23M | -$105.51M | -$46.05M | -$26.77M | -$8.55M | -$12.76M | -$24.52M | -$56.47M | -$43.39M | -$16.52M |
| EPS (Diluted) | $1.40 | $-2.28 | $-1.30 | $-0.78 | $-2.11 | $-3.21 | — | — | — | — |
| Total Assets | $284.73M | $178.13M | $172.33M | $115.34M | $132.94M | $11.21M | $10.51M | $26.75M | $52.46M | $84.89M |
| Total Liabilities | $130.07M | $138.46M | $110.46M | $40.22M | $5.82M | $77.62M | $84.96M | $93.31M | $109.97M | $103.58M |
| Shareholders' Equity | $154.66M | $39.67M | $61.86M | $75.12M | $101.66M | -$66.41M | -$74.46M | -$66.57M | -$57.52M | -$18.70M |
| Cash & Equivalents | $62.41M | $33.78M | $43.05M | $65.47M | $112.35M | $4.21M | $3.22M | $18.41M | $10.87M | $16.76M |
| Operating Cash Flow | -$1.60M | -$69.67M | -$33.53M | -$18.72M | $10.44M | -$1.94M | -$23.74M | -$54.20M | -$33.10M | -$29.77M |
| Capital Expenditures | $835.0K | $0 | $296.0K | $93.0K | $102.0K | $33.0K | $26.0K | $21.0K | $181.0K | $643.0K |
| Shares Outstanding | 56.85M | 53.67M | 41.53M | 34.54M | 35.01M | 4.54M | 2.27M | 1.65M | 14.66M | 14.65M |